arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Silo Pharma, Inc.

SILO

$3.69 ▼ -0.87 (-19.08%) at close

12 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Silo Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $30.9M

Dividend Yield —

Revenue Growth 0.0%

Op. Margin —

ROIC -53.6% ↗

FCF / Share $-0.56 ↗

Trailing P/E —

Price / Book 7.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$72.10K

— 0.0% —

Net Income Profit after all expenses

$-4.23M

↑ +3.8% —

FCF / Share Free cash flow per share

$-0.56

↑ +46.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Revenue Growth YoY (%)	0.0% Caution → Caution Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	58.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	0.8% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	N/M	—	—	—	—	—	—	—
Net Income Growth YoY (%)	3.8% Caution ↑ Caution Improving Year-over-year change in net income	-18.7% Weak Weak Year-over-year change in net income	5.3% Fair Fair Year-over-year change in net income	N/M	N/M	-199.8% Weak Weak Year-over-year change in net income	-4.5% Weak Weak Year-over-year change in net income	N/M	N/M	-2244.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	46.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	0.5% Caution ↑ Caution Improving Year-over-year change in free cash flow	31.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-6276.5% Weak Weak Year-over-year change in free cash flow	-36.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	0.0% Weak Weak Compound annual revenue growth over 3 years	—	—	21.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	12.2% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
FCF / Net Income (x)	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.58x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.38x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.28x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.80x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.06x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Return on Invested Capital (%)	-53.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-73.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-49.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-135.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3210.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-115.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-32.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-56.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-63.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-154.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-188.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-69.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-29.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-67.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-547%)	-87.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-682%)	-59.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-499%)	-37.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-352%)	43.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+187%)	-237.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1681%)	—	-237.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1686%)	29.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+98%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Interest Coverage (x)	-114.76x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-925.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-791.87x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1649.68x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-50821.17x Weak Weak Operating income divided by interest expense Optimal: > 5x	-27521.49x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-4.75M	$-3.91M	$-3.52M	$-11.37M	$-9.84M	$-1.13M	$-111.75K	$-336.68K	$-294.59K	$-279.00	$-1.75K	$0.00

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Revenue per Share (USD)	$0.01	$0.02	$0.02	$0.03	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.50	$-1.19	$-1.20	—	$0.04	$-0.05	—	—	$0.01	—	—	—
Free Cash Flow per Share (USD)	$-0.56	$-1.04	$-1.05	$-1.53	$-0.02	$-0.02	—	—	—	—	—	—
Book Value per Share (USD)	$0.47	$1.12	$2.13	$3.27	$0.09	$0.02	$-0.00	$0.02	$0.02	$-0.00	$-0.00	—
Tangible Book Value per Share (USD)	$0.46	$1.07	$2.13	$3.27	$0.09	$0.02	$-0.00	$0.02	$0.02	$-0.00	$-0.00	—
Basic Weighted Avg Shares (shares)	8.38M	3.68M	3.08M	2.28M	94.87M	65.95M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Working Capital (USD)	$6.74M	$5.46M	$6.91M	$11.14M	$9.91M	$1.28M	$377.11K	$578.00K	$1.60M	$-25.41K	$-1.75K	$47.48K
Total Equity (USD)	$6.31M	$5.03M	$6.18M	$10.34M	$9.06M	$1.28M	$-22.89K	$407.44K	$1.20M	$-41.19K	$-1.75K	—

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2012 10-K ↗	FY 2015 Dec 31, 2011 10-K ↗	FY 2014 Dec 31, 2010 10-K ↗
Sales/Revenue/Turnover (USD)	$72.10K	$72.10K	$72.10K	$72.10K	—	—	$40.57K	—	—	—	—	—
Net Income, GAAP (USD)	$-4.23M	$-4.39M	$-3.70M	$-3.91M	$3.90M	$-3.04M	$-1.01M	$-969.46K	$356.54K	$-1.17M	$-49.80K	—
Operating Cash Flow (USD)	$-4.66M	$-3.83M	$-3.22M	$-3.50M	$-2.28M	$-1.16M	$-794.32K	$272.64K	$-284.62K	$-71.28K	$-46.30K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 49 quarters

Silo Pharma, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SILO with peers